Explore the latest advancements in bispecific antibodies for multiple myeloma, focusing on early treatment opportunities and innovative trial designs.

Every immunoassay exploits the ability of an antibody (referred to as a primary antibody) to bind selectively to a particular target antigen, which is usually presented in a complex fluid such as ...

Alfa Cytology offers specialized radiolabeling and antibody-radionuclide conjugate development to advance radiopharmaceutical ...

A conjugated or labeled antibody is a polyclonal or monoclonal antibody with an attached reporter molecule that generates a signal through color, fluorescence, radioactivity, or enzymatic activity, ...

You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...

GSK’227 is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. The Food and Drug Administration (FDA) has ...

A lack of targeting specificity has been a long-running problem for cytotoxic anticancer agents, with excess side effects limiting their effectiveness. Scientists have turned to antibodies, and their ...

Daiichi Sankyo’s development of antibody-drug conjugates continues to hit turbulence. | Daiichi Sankyo’s development of ADCs ...

Genentech's native HIC-MS method uses ammonium tartrate, enabling efficient MS detection without compromising chromatographic ...

These complex biomolecules are specifically engineered to selectively deliver therapeutic agents to target cells by linking them to monoclonal antibodies. The safety profile and effectiveness of ADCs ...